BUZZ-Aeterna Zentaris Inc: Will complete late-stage study by year end

Tue Jan 19, 2016 11:17am EST
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Canadian drug developer's U.S.-listed shares up 27 pct at $3.39; Toronto-listed shares also gain 27 pct to C$4.88

** Says will complete by year-end a confirmatory late-stage trial of its drug for evaluating growth hormone deficiency

** Says it believes the study meets FDA and European regulators' design expectations for approval

* Expects to submit application for U.S. approval by mid-year 2017, if the study is successful

** Up to Friday's close, the U.S.-listed stock had fallen about 95 pct in the past 12 months